Jiuyuan Gene targets 31.13% public float through 136.30 million-share H-share conversion

Bulletin Express

Mar 25

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) has detailed a concrete timetable to resolve its public-float shortfall by converting 136.30 million unlisted domestic shares held by 12 shareholders into H shares.

The H-share full-circulation plan, approved at the 22 December 2025 extraordinary general meeting, was filed with the China Securities Regulatory Commission (CSRC) on 23 December 2025. Jiuyuan Gene anticipates receiving the CSRC’s filing notice by end-April 2026. Subject to regulatory review, all conversion procedures are slated for completion within the second quarter of 2026.

Assuming no other changes in the shareholdings of core connected persons, the conversion is expected to lift the company’s public float to approximately 31.13%, restoring compliance with Hong Kong’s minimum free-float requirement.

Management has committed to providing monthly updates on the restoration process and will release further announcements upon material developments. Shareholders and potential investors are advised to exercise caution when trading the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1162272003"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162272003\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162272003?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162272003","market":"us","top_or_hot":-1,"title":"Jiuyuan Gene targets 31.13% public float through 136.30 million-share H-share conversion","media":"Bulletin Express","content":"<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) has detailed a concrete timetable to resolve its public-float shortfall by converting 136.30 million unlisted domestic shares held by 12 shareholders into H shares.</p>\n<p>The H-share full-circulation plan, approved at the 22 December 2025 extraordinary general meeting, was filed with the China Securities Regulatory Commission (CSRC) on 23 December 2025. Jiuyuan Gene anticipates receiving the CSRC’s filing notice by end-April 2026. Subject to regulatory review, all conversion procedures are slated for completion within the second quarter of 2026.</p>\n<p>Assuming no other changes in the shareholdings of core connected persons, the conversion is expected to lift the company’s public float to approximately 31.13%, restoring compliance with Hong Kong’s minimum free-float requirement.</p>\n<p>Management has committed to providing monthly updates on the restoration process and will release further announcements upon material developments. Shareholders and potential investors are advised to exercise caution when trading the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiuyuan Gene targets 31.13% public float through 136.30 million-share H-share conversion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiuyuan Gene targets 31.13% public float through 136.30 million-share H-share conversion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-25 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) has detailed a concrete timetable to resolve its public-float shortfall by converting 136.30 million unlisted domestic shares held by 12 shareholders into H shares.</p>\n<p>The H-share full-circulation plan, approved at the 22 December 2025 extraordinary general meeting, was filed with the China Securities Regulatory Commission (CSRC) on 23 December 2025. Jiuyuan Gene anticipates receiving the CSRC’s filing notice by end-April 2026. Subject to regulatory review, all conversion procedures are slated for completion within the second quarter of 2026.</p>\n<p>Assuming no other changes in the shareholdings of core connected persons, the conversion is expected to lift the company’s public float to approximately 31.13%, restoring compliance with Hong Kong’s minimum free-float requirement.</p>\n<p>Management has committed to providing monthly updates on the restoration process and will release further announcements upon material developments. Shareholders and potential investors are advised to exercise caution when trading the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02566","symbol_name":"九源基因","start_time":0,"source_url":"","article_id":"1162272003","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162272003","pubTimestamp":1774428048,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) has detailed a concrete timetable to resolve its public-float shortfall by converting 136.30 million unlisted domestic shares held...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02566":"九源基因"},"translate_title":"九原基因通过13630万股H股转换目标公众持股量31.13%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02566":1},"content_text":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) has detailed a concrete timetable to resolve its public-float shortfall by converting 136.30 million unlisted domestic shares held by 12 shareholders into H shares.\nThe H-share full-circulation plan, approved at the 22 December 2025 extraordinary general meeting, was filed with the China Securities Regulatory Commission (CSRC) on 23 December 2025. Jiuyuan Gene anticipates receiving the CSRC’s filing notice by end-April 2026. Subject to regulatory review, all conversion procedures are slated for completion within the second quarter of 2026.\nAssuming no other changes in the shareholdings of core connected persons, the conversion is expected to lift the company’s public float to approximately 31.13%, restoring compliance with Hong Kong’s minimum free-float requirement.\nManagement has committed to providing monthly updates on the restoration process and will release further announcements upon material developments. Shareholders and potential investors are advised to exercise caution when trading the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}